Table 5.
Nonbiologic and biologic treatment combinations in first-line therapy in patients with moderate-to-severe UC or CD.
| Drug received in the first line | Azathioprine | Methotrexate | Mesalazine | Prednisolone | Othera | Total receiving combination |
|---|---|---|---|---|---|---|
| UC (n = 587) | 83 | |||||
| Infliximab (n = 256) | 18 (7.0) | 5 (2.0) | 4 (1.6) | 1 (0.4) | 13 (5.1) | 41 |
| Infliximab biosimilars | ||||||
| CT-P13 (n = 62) | 10 (16.1) | 0 | 2 (3.2) | 0 | 5 (8.1) | 17 |
| SB2 (n = 11) | 1 (9.1) | 0 | 0 | 0 | 0 | 1 |
| Adalimumab (n = 189) | 3 (1.6) | 0 | 5 (2.6) | 3 (1.6) | 5 (2.6) | 16 |
| Adalimumab biosimilars (n = 3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Golimumab (n = 21) | 0 | 1 (4.8) | 1 (4.8) | 1 (4.8) | 1 (4.8) | 4 |
| Vedolizumab (n = 37) | 1 (2.7) | 1 (2.7) | 1 (2.7) | 0 | 1 (2.7) | 4 |
| CD (n = 417) | 48 | |||||
| Infliximab (n = 154) | 8 (5.2) | 5 (3.2) | 1 (0.6) | 2 (1.3) | 6 (3.9) | 22 |
| Infliximab biosimilars | ||||||
| CT-P13 (n = 47) | 3 (6.4) | 0 | 0 | 0 | 4 (8.5) | 7 |
| SB2 (n = 5) | 1 (20.0) | 0 | 0 | 0 | 0 | 1 |
| Adalimumab (n = 153) | 4 (2.6) | 1 (0.7) | 0 | 1 (0.7) | 9 (5.9) | 15 |
| Adalimumab biosimilars | ||||||
| SB5 (n = 5) | 1 (20.0) | 0 | 0 | 0 | 0 | 1 |
| Vedolizumab (n = 21) | 0 | 1 (4.8) | 0 | 0 | 1 (4.8) | 2 |
Values are n (%); proportions based on number of patients who received the biologic treatment. Combinations defined as any treatment administered on the same day as or after biologic treatment initiation. Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis.
Other treatments included beclometasone dipropionate, budesonide, ciprofloxacin, cyclosporine, hydrocortisone, mercaptopurine, methylprednisolone, metronidazole, olsalazine, prednisone, sulfasalazine, or any combination of any of the drugs listed in this table.